Investor Confidence Shakens After Century Therapeutics Inc (NASDAQ: IPSC) Share Prices Gain $0.09

Century Therapeutics Inc (NASDAQ:IPSC) has a beta value of 1.44 and has seen 1.12 million shares traded in the last trading session. The company, currently valued at $107.87M, closed the last trade at $1.30 per share which meant it gained $0.09 on the day or 7.44% during that session. The IPSC stock price is -323.85% off its 52-week high price of $5.51 and 12.31% above the 52-week low of $1.14. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.47 million shares traded. The 3-month trading volume is 388.80K shares.

The consensus among analysts is that Century Therapeutics Inc (IPSC) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.44.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Century Therapeutics Inc (NASDAQ:IPSC) trade information

Sporting 7.44% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IPSC stock price touched $1.30 or saw a rise of 9.41%. Year-to-date, Century Therapeutics Inc shares have moved -60.84%, while the 5-day performance has seen it change 4.00%. Over the past 30 days, the shares of Century Therapeutics Inc (NASDAQ:IPSC) have changed -6.47%. Short interest in the company has seen 3.52 million shares shorted with days to cover at 10.09.

Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 90.71% from current levels. The projected low price target is $5.0 while the price target rests at a high of $27.0. In that case, then, we find that the current price level is -1976.92% off the targeted high while a plunge would see the stock gain -284.62% from current levels.

Century Therapeutics Inc (IPSC) estimates and forecasts

Figures show that Century Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -60.61% over the past 6 months, with this year growth rate of 21.63%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 47.16%.

4 analysts offering their estimates for the company have set an average revenue estimate of 975k for the current quarter. 3 have an estimated revenue figure of 633.33k for the next ending quarter. Year-ago sales stood 268k and 855k respectively for this quarter and the next, and analysts expect sales will grow by 263.81% for the current quarter and 47.16% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 15.24% over the past 5 years.

IPSC Dividends

Century Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Century Therapeutics Inc (NASDAQ:IPSC)’s Major holders

Insiders own 28.36% of the company shares, while shares held by institutions stand at 59.50% with a share float percentage of 83.05%. Investors are also buoyed by the number of investors in a company, with Century Therapeutics Inc having a total of 102.0 institutions that hold shares in the company. The top two institutional holders are BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 5.41 million shares worth more than $13.8 million. As of 2024-06-30, BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC held 8.6848% of shares outstanding.

The other major institutional holder is VR ADVISER, LLC, with the holding of over 5.39 million shares as of 2024-06-30. The firm’s total holdings are worth over $13.74 million and represent 8.651% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 1.22% shares in the company for having 1.04 shares of worth $1.35 million while later fund manager owns 785.57 shares of worth $1.02 million as of Jun 30, 2024 , which makes it owner of about 0.92% of company’s outstanding stock.